Stock A095700 GENEXINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genexine, Inc.

Equities

A095700

KR7095700001

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
7,280 KRW -0.95% Intraday chart for Genexine, Inc. +3.41% -26.46%
2023 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 1,485,081 3,069,933 1,459,198 470,211 410,353
Enterprise Value (EV) 1 1,441,942 3,090,374 1,483,621 532,352 413,298
P/E ratio -80.7 x 142 x -30.2 x -8.34 x -5.99 x
Yield - - - - -
Capitalization / Revenue 131 x 166 x 39.6 x 29.1 x 92.7 x
EV / Revenue 128 x 167 x 40.3 x 33 x 93.4 x
EV / EBITDA -34.3 x -85.3 x -93.9 x -18.5 x -11.2 x
EV / FCF - -102,001,939 x -30,763,335 x -5,500,948 x -13,646,659 x
FCF Yield - -0% -0% -0% -0%
Price to Book 5 x 5.73 x 2.84 x 1.72 x 1.38 x
Nbr of stocks (in thousands) 30,890 32,107 32,538 32,688 41,450
Reference price 2 48,077 95,615 44,846 14,385 9,900
Announcement Date 3/12/21 3/12/21 3/17/22 3/20/23 3/13/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 11,303 18,543 36,828 16,139 4,427
EBITDA 1 -42,070 -36,231 -15,801 -28,808 -36,897
EBIT 1 -44,573 -39,151 -19,099 -33,680 -41,928
Operating Margin -394.35% -211.13% -51.86% -208.69% -947.19%
Earnings before Tax (EBT) 1 -16,509 27,536 -48,876 -56,831 -66,860
Net income 1 -16,509 27,570 -48,042 -55,974 -66,874
Net margin -146.06% 148.68% -130.45% -346.82% -1,510.71%
EPS 2 -595.4 671.5 -1,483 -1,724 -1,652
Free Cash Flow - -30,297 -48,227 -96,775 -30,286
FCF margin - -163.38% -130.95% -599.63% -684.17%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/12/21 3/12/21 3/17/22 3/20/23 3/13/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3
Net sales 1 0.357
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income -
Net margin -
EPS -
Dividend per Share -
Announcement Date 11/15/23
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - 20,441 24,423 62,141 2,945
Net Cash position 1 43,139 - - - -
Leverage (Debt/EBITDA) - -0.5642 x -1.546 x -2.157 x -0.0798 x
Free Cash Flow - -30,297 -48,227 -96,775 -30,286
ROE (net income / shareholders' equity) - 6.61% -9.26% -14.3% -23.3%
ROA (Net income/ Total Assets) - -5.12% -1.94% -4.1% -6.85%
Assets 1 - -538,051 2,482,781 1,363,655 976,584
Book Value Per Share 2 9,612 16,682 15,795 8,341 7,156
Cash Flow per Share 2 617.0 162.0 854.0 549.0 146.0
Capex 1 3,962 22,208 56,433 31,747 7,273
Capex / Sales 35.05% 119.76% 153.23% 196.71% 164.3%
Announcement Date 3/12/21 3/12/21 3/17/22 3/20/23 3/13/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENEXINE, INC. Stock Genexine, Inc.
-26.46% 219M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A095700 Stock
  4. Financials Genexine, Inc.